Physicians' attitudes toward gastroprotective strategies for nonsteroidal anti-inflammatory drug prescription.

Introduction: There is a paucity of information regarding providers' attitudes toward gastric-protective strategies with concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs). We aimed to assess gastric-protective strategies used upon prescribing NSAIDs and providers' awareness of societal guidelines for preventing NSAID-induced gastric complications.

Methods: A standardized 10-item questionnaire was sent to all orthopedic providers in North Carolina and South Carolina.

Correction: Habib et al. Thiolated Chitosan Microneedle Patch of Levosulpiride from Fabrication, Characterization to Bioavailability Enhancement Approach. 2022, , 415.

In the original publication [...

Classic biphasic pulmonary blastoma with endobronchial invasion in a 16-year-old male: A rare case report.

Pulmonary blastoma (PB) is a rare and aggressive lung neoplasm, representing 0.25 %-0.50 % of lung cancers and characterized by biphasic histology with both epithelial and mesenchymal components.

A state-of-the-art review on lignocellulosic biomass-derived activated carbon for adsorption and photocatalytic degradation of pollutants: a property and mechanistic study.

A promising water treatment method involves using biomass-derived activated carbon (AC) to remove emerging pollutants from wastewater due to its adsorption capacity, cost-effectiveness, and sustainability. Notwithstanding, the existing literature lacks comprehensive studies that specifically focus on removing contaminants in water by comparing the effectiveness of adsorption and photocatalytic degradation methods. Additionally, there is not much emphasis on analyzing the combined processes of adsorption-photocatalytic degradation utilizing AC.

Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.

Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years. Recent therapies, notably immunotherapy and targeted therapy, have significantly improved the outcome of patients with metastatic melanoma. Previously dismal five-year survival rates of below 5% have shifted to over 50% of patients surviving the five-year mark, marking a significant shift in the landscape of melanoma treatment and survival.